Rogers Corporation - SIC # 3673 -

Ticker Exchange SIC # Website Latest Ticker
ROG New York 3673 www.rogerscorp.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Rogers Corporation

Rogers (ROG) Dropped, What Is Behind The Fresh Attention? - Nov 6th, 2026 7:14 am
ROG Q3 deep dive: margin expansion and design wins drive positive outlook - Oct 30th, 2026 8:03 pm
5 insightful analyst questions from Rogers’s Q3 earnings call - Oct 30th, 2026 5:07 am
Rogers (ROG) Q3 Earnings Highlight Margin Strength Despite Ceramic Drag - Oct 29th, 2026 11:19 pm
Rogers (ROG) stock trades up, here is why - Oct 28th, 2026 9:18 pm
Rogers Corp.: Q3 Earnings Snapshot - Oct 28th, 2026 12:36 pm
Why Rogers Stock Popped 13% at the Open Before Cooling Off - Oct 28th, 2026 11:01 am
Rogers (ROG) Stock Looks Above Fair Value After Its 56% Rebound - Oct 28th, 2026 4:28 am
Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma - Oct 28th, 2026 12:00 am
Rogers Corporation Q3 2026 Earnings Call Summary - Oct 27th, 2026 6:46 pm
Rogers (ROG) Q3 2026 Earnings Call Transcript - Oct 27th, 2026 5:28 pm
Rogers Q3 Earnings Call Highlights - Oct 27th, 2026 5:04 pm
Rogers Corp. (ROG) Beats Q3 Earnings Estimates - Oct 27th, 2026 3:20 pm
Rogers (NYSE:ROG) misses Q3 2026 sales expectations - Oct 27th, 2026 2:31 pm
Rogers Corporation Reports Third Quarter 2026 Results - Oct 27th, 2026 2:05 pm
Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories - Oct 27th, 2026 12:00 am
Rogers (ROG) to report earnings tomorrow: here is what to expect - Oct 25th, 2026 10:54 pm
Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer - Oct 25th, 2026 9:30 am
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN) - Oct 23rd, 2026 11:30 am